Oral enzyme therapy for celiac sprue

Area of Science:

• Gastroenterology
• Immunology
• Biochemistry

Background:

• Celiac sprue is an inflammatory small intestine disease triggered by dietary gluten.
• Understanding the molecular pathogenesis of celiac sprue has paved the way for novel therapeutic strategies.
• Current treatment involves a strict, lifelong gluten-free diet.

Purpose of the Study:

• To explore the challenges and strategies for the discovery and preclinical development of oral enzyme therapies for celiac sprue.
• To assess methods for identifying, producing, and optimizing gluten-degrading enzymes (glutenases).

Main Methods:

• Review of key challenges in oral enzyme therapy development for celiac sprue.
• Description and critical assessment of methods for lead identification and assay development.
• Evaluation of techniques for gram-scale production, formulation, and lead optimization of proteases.

Main Results:

• Identification of immunodominant gluten peptides and their pathogenic properties.
• Elucidation of molecular mechanisms underlying celiac sprue immunopathology.
• Advancement in understanding disease pathogenesis enables rational drug design.

Conclusions:

• Oral enzyme therapy, using glutenases to detoxify gluten in situ, is a clinically advanced therapeutic strategy.
• Addressing challenges in enzyme discovery and development is crucial for effective oral enzyme therapies.
• Further research and development are needed to optimize next-generation proteases for celiac sprue treatment.